Department of Vascular Surgery, Attikon University Hospital, Medical School, Athens, Greece.
Biomark Med. 2010 Aug;4(4):601-9. doi: 10.2217/bmm.10.79.
Carotid atherosclerosis constitutes an important cause of ischemic brain attack and stroke, accounting for up to 40% of cases of ischemic cerebrovascular disease. Type 2 diabetes mellitus is an independent risk factor for stroke and its recurrence. Thus, identifying diabetic patients who are at high risk of developing stroke is of great clinical importance. Noninvasive measurements of surrogate markers of atherosclerosis, such as novel serum biomarkers, can be helpful in detecting subclinical carotid disease, especially among individuals at the highest cardio-/cerebro-vascular risk. Previous studies have proposed an expanding body of serum biomarkers, such as C-reactive protein, fibrinogen, adipokines, cytokines and growth factors, as novel indicators of carotid atherosclerosis development that predict carotid-related clinical outcomes. Furthermore, those biomarkers are expected to assess the efficacy of both pharmaceutical and interventional strategies. Accordingly, it is increasingly clear that measuring biomarkers may improve the definition of cerebrovascular risk profile in patients with Type 2 diabetes mellitus.
颈动脉粥样硬化是缺血性脑卒中和中风的重要原因，占缺血性脑血管病的 40%。2 型糖尿病是中风及其复发的独立危险因素。因此，识别发生中风风险较高的糖尿病患者具有重要的临床意义。非侵入性测量动脉粥样硬化的替代标志物，如新型血清生物标志物，有助于检测亚临床颈动脉疾病，尤其是在心血管/脑血管风险最高的人群中。先前的研究提出了越来越多的血清生物标志物，如 C 反应蛋白、纤维蛋白原、脂肪因子、细胞因子和生长因子，作为预测颈动脉相关临床结局的颈动脉粥样硬化发展的新型指标。此外，这些生物标志物有望评估药物和介入策略的疗效。因此，越来越明显的是，测量生物标志物可以改善 2 型糖尿病患者的脑血管风险状况的定义。
